solexa

Genetic Future

Category archives for solexa

Jay Flatley, CEO of sequencing giant Illumina, announced at the Consumer Genetics Conference today that the company had reduced the price of its retail whole-genome sequencing service. At $19,500 this still isn’t in the realm of an impulse buy for most of us, but it’s a long way down from the $48,000 that Illumina offered at…

Zoe McDougall from Oxford Nanopore points me to a press release from Illumina announcing a new era of celebrity genomics: Illumina, Inc. (NASDAQ:ILMN) today announced that it has sequenced the DNA of American actress Glenn Close, the first publicly named female to have her DNA sequenced to full coverage. The service was completed in Illumina’s…

The main theme of this year’s Advances in Genome Biology and Technology meeting should come as no surprise to regular readers: sequencing. Generating as many bases of DNA sequence as quickly, cheaply and accurately as possible is the goal of the moment, and the number of companies jostling to achieve that goal is growing rapidly.…

Belated news from AGBT

I’ve been remiss in blogging from the Advances in Genome Biology and Technology meeting here in Marco Island, Florida, primarily due to some panic-stricken last-minute changes to the slides for my own presentation last night. Fortunately the conference has been extremely well-covered by others: Sanger colleague Luke Jostins has blog posts up summarising day 1…

The big news from the JP Morgan investment conference today is the announcement of a brand new shiny sequencing machine from Illumina, the HiSeq 2000. The new machine boasts an impressive set of statistics, and looks likely to gradually replace Illumina’s GAIIx as the workhorse of most modern sequencing facilities. So, how excited should we…

Sequencing giant Illumina has announced that it has delivered its first commercial personal genome sequence. The sequence was generated by the genome sequencing service launched by Illumina back in June, and was delivered in collaboration with new personal genomics company Pathway Genomics. Illumina’s genome sequencing service costs $48,000, and its first customer was entrepreneur Hermann…

I’ve just discovered a very promising new blog in the genomics sphere (well, technically it’s a newly relaunched blog) run by a group at the University of Birmingham. Two posts by Nick Loman are of immediate interest to readers here. Firstly, I highly recommend Nick’s thorough dissection of accusations made by Applied Biosystems’ Kevin McKernan in a recent…

The buzz leading up to this week’s Consumer Genetics Show in Boston suggested that a major announcement would be made by the CEO of genomics technology provider Illumina, Jay Flatley. Illumina provides the most popular second-generation sequencing instrument currently on the market, the Genome Analyzer II, and has been making noises about moving into the…

BioArray News (subscription required) reports that genomic analysis technology provider Illumina has launched a new family of genotyping chips designed to simultaneously assay 4 million sites of variation in the human genome.

Regular readers will know that I’m at the Advances in Genome Biology and Technology (AGBT) meeting this week, one of the most highly-awaited meetings on the genomics calendar. There’s a huge amount of fascinating data being presented (anyone interested in a blow-by-blow account should follow Anthony Fejes’ live-blogging), but there’s definitely an overarching theme: the…